Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A.

N Engl J Med. 2008 Oct 9;359(15):1631-3. doi: 10.1056/NEJMc0805274. No abstract available.


Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.

Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.

J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.


Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Dimitrova M, Castellino F, Nicholson K, Del Giudice G, Golding H.

PLoS One. 2014 Apr 22;9(4):e95496. doi: 10.1371/journal.pone.0095496. eCollection 2014.


Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.

Wu J, Wang F, Fang F, Zhang W, Chang H, Zheng L, Chen Z.

Arch Virol. 2011 Mar;156(3):387-95. doi: 10.1007/s00705-010-0860-4. Epub 2010 Nov 26.


Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.


Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.

Vaccine. 2010 Jan 8;28(3):840-8. doi: 10.1016/j.vaccine.2009.10.019. Epub 2009 Oct 14.


Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.

Lopez P, Caicedo Y, Sierra A, Tilman S, Clemens R, Banzhoff A.

Clin Vaccine Immunol. 2013 May;20(5):753-8. doi: 10.1128/CVI.00626-12. Epub 2013 Mar 27.


A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.

Herbinger KH, von Sonnenburg F, Nothdurft HD, Perona P, Borkowski A, Fragapane E, Nicolay U, Clemens R.

Hum Vaccin Immunother. 2014;10(1):92-9. doi: 10.4161/hv.26495. Epub 2013 Sep 20.


Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M.

Vaccine. 2003 Apr 2;21(15):1687-93.


Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I.

N Engl J Med. 2009 Dec 17;361(25):2424-35. doi: 10.1056/NEJMoa0907650. Epub 2009 Sep 10.


Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM.

Hum Vaccin Immunother. 2015;11(3):553-63. doi: 10.1080/21645515.2015.1011562. Review.


A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.

Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A.

Clin Vaccine Immunol. 2010 Nov;17(11):1817-9. doi: 10.1128/CVI.00461-09. Epub 2010 Sep 1.


Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.

Gillard P, Giet D, Heijmans S, Dramé M, Walravens K, Roman F.

Trials. 2014 Oct 29;15:419. doi: 10.1186/1745-6215-15-419.


Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.

Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R.

Hum Vaccin Immunother. 2012 Jul;8(7):921-8. doi: 10.4161/hv.20248. Epub 2012 Jul 1.


Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.

Pediatrics. 2010 Oct;126(4):e762-70. doi: 10.1542/peds.2009-2628. Epub 2010 Sep 6.


Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.

Díez-Domingo J, Baldó JM, Planelles-Catarino MV, Garcés-Sánchez M, Ubeda I, Jubert-Rosich A, Marès J, Garcia-Corbeira P, Moris P, Teko M, Vanden Abeele C, Gillard P.

Influenza Other Respir Viruses. 2015 Mar;9(2):68-77. doi: 10.1111/irv.12295. Epub 2015 Feb 5.


AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.

Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, Godeaux O, Izurieta P, Vaughn DW.

J Infect Dis. 2015 Mar 1;211(5):801-10. doi: 10.1093/infdis/jiu548. Epub 2014 Oct 6.


Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E.

Clin Vaccine Immunol. 2012 Dec;19(12):1943-8. doi: 10.1128/CVI.00373-12. Epub 2012 Oct 17.


The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.

Wei SH, Liu MT, Tsai YC, Liao CH, Chen CM, Wang WY, Huang YL, Chang FY, Chou P.

BMC Infect Dis. 2014 Nov 14;14:587. doi: 10.1186/s12879-014-0587-z.


A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.

Naruse T, Fukuda T, Tanabe T, Ichikawa M, Oda Y, Tochihara S, Kimachi K, Kino Y, Ueda K.

Vaccine. 2015 Nov 9;33(45):6078-84. doi: 10.1016/j.vaccine.2015.09.022. Epub 2015 Sep 25.


Supplemental Content

Support Center